IPM Take
Rare-disease access does not begin on the day a regulator says yes.
It begins earlier: in decisions over who will file in each country, who will support early access, who understands fragmented national systems, and whether the organisation holding the rights has the infrastructure to reach patients beyond one priority market.
Ionis’ agreement with Recordati does not make zilganersen available. It decides who will be responsible for trying to make availability possible outside the United States.
That work is not peripheral. In rare disease, it is the difference between a medicine being announced globally and becoming reachable globally.
Executive Summary
Ionis has granted Recordati exclusive rights to develop and commercialise zilganersen for Alexander disease in all countries outside the United States. Ionis will retain sole US commercial responsibility and continue to lead global development.
Recordati will manage regulatory filings and commercialisation outside the United States, including country-specific support for early-access pathways where local regulations and access conditions allow. Ionis will receive a $30 million upfront payment, with additional potential milestones and tiered royalties of up to the mid-20% range on annual net sales.
Zilganersen remains investigational. Its US New Drug Application is under FDA Priority Review, with a target action date of 22 September 2026. No regulator has approved it yet.
Why it matters
- Patients / advocates: A treatment can be scientifically promising and still remain unreachable outside the first country to review it. Global access needs a plan before approval, not a press release after it.
- Regulators: Early-access and regulatory routes for ultra-rare conditions require local capability. A central development programme cannot replace country-level decisions.
- Industry / innovation partners: Commercial infrastructure is not separate from patient impact. It determines whether a medicine reaches a clinic, a national system or only a conference slide.
A licensing agreement can sound like finance news.
For people living with Alexander disease, it is more consequential than that.
Alexander disease is a rare, progressive and often fatal neurological condition caused by disease-causing variants in the GFAP gene. It can lead to progressive neurological deterioration, loss of mobility and independence, and problems affecting swallowing and airway protection. There are no approved disease-modifying medicines.
Zilganersen is an investigational antisense therapy designed to reduce excess GFAP production. Ionis has reported positive pivotal-study results, including stabilisation of gait speed at week 61 in participants aged five years and older. Those results are important, but they remain company-reported and the treatment remains under review.
That is why the Recordati agreement matters now.
Regulatory authorisation, if it comes, will not create country filing strategies, prepare local evidence for decision-makers, identify specialist centres, support early-access requests or build a route through very different health systems. Those are the dull, difficult tasks that determine whether a family ever hears about a potential treatment in time to ask for it.
The agreement does not guarantee reimbursement. It does not guarantee availability. It does not guarantee equitable access.
But it creates an accountable structure for the work that has to happen after the science leaves the laboratory and before it reaches a patient.
